Previous 10 | Next 10 |
The global economic recovery can be attributed in large measure to the efforts of several healthcare companies in their race to develop a COVID-19 vaccine. With governments now pouring billions of dollars to further improve the healthcare industry, and companies in the sector focusing on meet...
Amneal Pharmaceuticals (AMRX) announces that the U.S. FDA has accepted for review the Biologics License Application ((BLA)) for Bevacizumab for the treatment of metastatic colorectal cancer.Shares up more than 8% premarket.The health regulator has also set a standard review goal dat...
- Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Food and Drug Administration recently accepted Amneal’s 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinj...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q1 2021 Earnings Call May 7, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcr...
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Conference Call May 07, 2021, 08:30 ET Company Participants Anthony DiMeo - IR Chintu Patel - Co-Founder, Co-CEO & Director Chirag Patel - Co-Founder, Co-CEO, President & Director Anastasios Konidaris - EVP & CFO Joseph Todisco ...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Amneal Pharmaceuticals (AMRX) posted first-quarter revenue that fell short of Wall Street estimates, partly hurt by decreased influenza activity during the period, and maintained its full-year forecast.Revenue during the quarter fell 1% to $493.1M, due to the higher customer pu...
Amneal Pharmaceuticals (AMRX): Q1 Non-GAAP EPS of $0.20 beats by $0.02; GAAP EPS of $0.04 misses by $0.03.Revenue of $493.1M (-1.1% Y/Y) misses by $19.59M.Press Release For further details see: Amneal Pharmaceuticals EPS beats by $0.02, misses on revenue
‒ Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.20 ‒ ‒ Maintaining 2021 Full Year Financial Ou...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...